FDA Approved: LASTACAFT — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

FDA approved a supplemental application for LASTACAFT (alcaftadine) by Allergan, Inc., resulting in a labeling change following the supplemental submission.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• Lastacaft (Alcaftadine)

Snippet

SUPPL AP for LASTACAFT (ALCAFTADINE)